Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

After Copycat Boom, China's Drugmakers Target Global Generics

China-based drugmakers that once fueled a surge of copycat weight-loss treatments in the U.S. are now pivoting to generics of Novo Nordisk‘s (NYSE:NVO) Wegovy and Eli Lilly's (NYSE:LLY) Zepbound as regulators tighten rules on compounded medicines.

Benzinga

Insiders Bought the Selloff in Eli Lilly. Should You Buy LLY Stock, Too?

What traders need to know about recent insider buying on LLY stock, and how to track insider moves using Barchart tools.

Barchart

Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death

Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Benzinga Bulls And Bears: Eli Lilly, Firefly, Marvell — And Trump Investment Hints Boost Defense Stocks

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Benzinga

What is the cheapest weight loss drug available in the UK?

We compared the prices of weight loss drugs licensed as prescription medication in the UK

Evening Standard

Mounjaro vs Wegovy: Cost, side effects and how to buy weight-loss jabs safely

The cost of Mounjaro is about to increase, which has got many users considering switching to Wegova. Here we take a look at the differences between the two weight-loss drugs

The Independent UK

Mounjaro price war breaks out as users scramble to find best deal

The price of the weight-loss drug Mounjaro will increase nationwide on Monday

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Stock: Is LLY Underperforming the Healthcare Sector?

Although Eli Lilly has trailed the broader healthcare sector over the past year, analysts maintain a strongly bullish outlook on the stock’s long-term growth potential.

Barchart

Cost of Mounjaro to be discounted in UK pharmacies

It comes after an announcement from Eli Lilly that the UK list price for the drug is set to rise from September 1.

Evening Standard

Eli Lilly to offer UK discount on Mounjaro weight-loss jabs

IN FULL

The Independent UK

Mounjaro weight-loss jab ‘to be offered at discounted prices to pharmacies’

Cost of drug still set to more than double after Donald Trump told manufacturers to raise charges outside US

The Independent UK

Stock Of The Day: Another Breakout For Eli Lilly?

Trading is quiet in Eli Lilly and Co (NYSE:LLY) on Thursday. The stock has stalled out at a resistance level.

Benzinga

Warning over Mounjaro ‘golden dose’ as users panic over shortages and soaring prices

With the price of Mounjaro to rise in September, some users are using leftover medication in syringes to create an extra dose

The Independent UK

UK Patients Scramble For Mounjaro As Eli Lilly's 170% Price Hike Plan Sparks Shortages, Health Fears

Patients across the United Kingdom are struggling to obtain the weight-loss and diabetes drug Mounjaro as demand surges ahead of a sharp price increase set for September.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Mounjaro maker pauses shipments of weight loss drug to UK

US firm Eli Lilly reportedly tells British wholesalers to stop taking orders as demand soars before September price rise

The Independent UK

Why Mounjaro sales to UK wholesalers have been suspended

IN FULL

Evening Standard

Mounjaro weight loss jab sales are halted in the UK as drugmaker looks to beat price rise

Eli Lilly, the manufacturer of Mounjaro, has temporarily suspended deliveries of the drug to UK pharmacies in response to ‘unprecedented demand’

Benzinga

This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Sales of Mounjaro weight loss jab to UK suspended as pharmacies hit by shortage ahead of price hike

Boots and Lloyds pharmacies among those running low after users stockpile drug ahead of price hike

Benzinga

New Eli Lilly Data Puts Verzenio In Breast Cancer Spotlight

Pharmaceutical advancements continue to reshape the landscape of cancer treatment, offering new hope for patients and altering market dynamics. Recent developments in innovative therapies demonstrate significant progress in survival outcomes for high-risk early breast cancer patients.

The Independent UK

‘I lost more than 2 stone on Mounjaro - but my hair started to fall out’

Rhiannon Anne Griffiths-Bowen says the weight-loss benefits of taking Mounjaro outweighed the issue of hair loss

Benzinga

Eli Lilly Stock Jumps On Weight-Loss Pill Trial

Eli Lilly and Co. (NYSE:LLY) stock has experienced significant volatility over the past six months, primarily driven by reactions to developments in its weight-loss drug portfolio.

MarketBeat

As the Market Rotates, This Healthcare ETF Is Leading the Way

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.

The Independent UK

Daily weight loss pill achieves main goal in late-stage trial

Data from an earlier study of the drug in patients without diabetes sent company shares tumbling

Benzinga

Eli Lilly's Obesity Pill Shows Big Wins In Weight, Blood Sugar And Heart Risk Factors

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral orforglipron in adults with obesity or overweight and type 2 diabetes.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.